Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL4766771 | 0.94 | KDM4E (0.58) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Butyric Acid SCHEMBL27742018 | 0.91 | KDM4E (0.49) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Succinic Acid SCHEMBL8083564 | 0.91 | KDM4E (0.55) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Acetic Acid SCHEMBL28378441 | 0.90 | KDM4E (0.62) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Acetic Acid SCHEMBL28378940 | 0.90 | KDM4E (0.62) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Acetic Acid SCHEMBL28658551 | 0.90 | KDM4E (0.62) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Acetic Acid SCHEMBL39490 | 0.90 | KDM4E (0.62) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Adipic Acid SCHEMBL10713644 | 0.89 | KDM4E (0.53) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Acetic Acid SCHEMBL17891250 | 0.88 | KDM4E (0.60) | KDM4EHSD17B10CDC25ACDC25BTDP1 | |
| Succinic Acid SCHEMBL8083562 | 0.88 | KDM4E (0.49) | KDM4EHSD17B10CDC25ACDC25BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 468 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119044-A2 | ADRULIPASE COMPOSITIONS | First Wave BioPharma, Inc. (US) | 2024-06-06 | — | — | WO | claimed |
| CN-116437947-A | Non-pig formulations and methods thereof | 第一浪潮生物制药有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2023114390-A2 | LIPASE FORMULATIONS AND METHODS THEREOF | First Wave BioPharma, Inc. (US) | 2023-06-22 | — | — | WO | claimed |
| EP-4167970-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | First Wave Biopharma, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| EP-3972569-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | Helm AG (DE) | 2022-03-30 | — | — | EP | claimed |
| WO-2021257843-A1 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | AZURRX BIOPHARMA, INC. (US) | 2021-12-23 | — | — | WO | claimed |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | claimed |
| WO-2020234448-A1 | NANOPARTICLES COMPRISING ENZALUTAMIDE | HELM AG (DE) | 2020-11-26 | — | — | WO | claimed |
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | claimed |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2020-07-21 | — | — | US | claimed |
| EP-1239835-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| WO-2002067893-A2 | PHARMACEUTICAL FORMULATION COMPRISING BICALUTAMIDE | ASTRAZENECA AB (SE) | 2002-09-06 | — | — | WO | claimed |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | BEND RESEARCH INC. | 2002-08-01 | — | — | US | claimed |
| US-20020006443-A1 | Drug in a solubility-improved form with a concentration-enhancing polymer such as hydroxypropyl methyl cellulose acetate succinate; combination improves bioavailability relative to a control of just solubility improved form | BEND RESEARCH, INC. | 2002-01-17 | — | — | US | claimed |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| WO-2001068055-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001068092-A2 | GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001047495-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | claimed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246271-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | KDM4E 675/4885HSD17B10 488/4885CDC25A 1047/4885 |
| US-20020103225-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | KDM4E 2729/4885HSD17B10 242/4885CDC25A 3846/4885 |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | KDM4E 675/4885HSD17B10 488/4885CDC25A 1047/4885 |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | PYGL, PYGM, GYS2 | KDM4E 2522/4885HSD17B10 261/4885CDC25A 1033/4885 |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | KDM4E 2299/4885HSD17B10 472/4885CDC25A 849/4885 |
| US-10716760-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | KDM4E 675/4885HSD17B10 488/4885CDC25A 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.